190 Results for "

BCR-ABL

" in MedChemExpress (MCE) Product Catalog:
Products (190)

190 Results for "BCR-ABL" in MCE Product Catalog:

179
179 Publications Verification
Cat. No.: HY-10181
CAS No.: 302962-49-8
Purity:  99.83%
Synonyms: BMS-354825
Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy, and can cross the blood-brain barrier .
loading...
    loading...
179
179 Publications Verification
Cat. No.: HY-10181A
CAS No.: 854001-07-3
Purity:  98.86%
Synonyms: BMS-354825 hydrochloride
Research Areas:  

Cancer

Dasatinib (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib hydrochloride inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib hydrochloride also induces apoptosis and autophagy.
loading...
    loading...
179
179 Publications Verification
Cat. No.: HY-10181B
CAS No.: 863127-77-9
Purity:  99.58%
Synonyms: BMS-354825 monohydrate
Research Areas:  

Cancer

Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib monohydrate inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib monohydrate also induces apoptosis and autophagy.
loading...
    loading...
128
128 Cited Publications
Cat. No.: HY-13520
CAS No.: 31430-18-9
Purity:  99.59%
Synonyms: Oncodazole; R17934
Research Areas:  

Cancer

Nocodazole (Oncodazole) is a rapidly-reversible inhibitor of microtubule. Nocodazole binds to β-tubulin and disrupts microtubule assembly/disassembly dynamics, which prevents mitosis and induces apoptosis in tumor cells. Nocodazole inhibits Bcr-Abl.
loading...
    loading...
127
127 Cited Publications
Cat. No.: HY-50946
CAS No.: 220127-57-1
Synonyms: STI571 Mesylate; CGP-57148B Mesylate
Imatinib Mesylate (STI571 Mesylate) is an orally active tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.
loading...
    loading...
127
127 Cited Publications
Cat. No.: HY-15463
CAS No.: 152459-95-5
Purity:  99.95%
Synonyms: STI571; CGP-57148B
Research Areas:  

Cancer

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
loading...
    loading...
52
52 Cited Publications
Cat. No.: HY-10159
CAS No.: 641571-10-0
Purity:  99.94%
Synonyms: AMN107
Target:  

Bcr-Abl Autophagy

Research Areas:  

Cancer

Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
loading...
    loading...
52
52 Cited Publications
Cat. No.: HY-10159A
CAS No.: 923288-90-8
Purity:  99.91%
Synonyms: AMN107 monohydrochloride monohydrate
Target:  

Bcr-Abl Autophagy

Research Areas:  

Cancer

Nilotinib monohydrochloride monohydrate is a second generation tyrosine kinase inhibitor (TKI), is significantly potent against BCR-ABL, and is active against many BCR-ABL mutants.
loading...
    loading...
52
52 Cited Publications
Cat. No.: HY-10159C
Synonyms: AMN107 hydrochloride dihydrate
Target:  

Autophagy Bcr-Abl

Research Areas:  

Cancer

Nilotinib (AMN107) hydrochloride dihydrate is an orally active Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity and can be used in studies of chronic myelogenous leukaemia .
loading...
    loading...
52
52 Cited Publications
Cat. No.: HY-10159B
CAS No.: 923288-95-3
Synonyms: AMN107 hydrochloride
Target:  

Bcr-Abl Autophagy

Research Areas:  

Cancer

Nilotinib (AMN107) hydrochloride is an orally active Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity and can be used in studies of chronic myelogenous leukaemia .
loading...
    loading...
21
21 Cited Publications
Cat. No.: HY-13264
CAS No.: 856243-80-6
Purity:  99.70%
Synonyms: WP1130
Research Areas:  

Cancer

Degrasyn (WP1130) is a cell-permeable deubiquitinase (DUB) inhibitor, directly inhibiting DUB activity of USP9x, USP5, USP14, and UCH37. Degrasyn has been shown to downregulate the antiapoptotic proteins Bcr-Abl and JAK2.
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-104010
CAS No.: 1492952-76-7
Purity:  99.61%
Synonyms: ABL001
Target:  

Bcr-Abl

Research Areas:  

Cancer

Asciminib (ABL001) is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-104010A
CAS No.: 2119669-71-3
Purity:  99.84%
Synonyms: ABL001 hydrochloride
Target:  

Bcr-Abl

Research Areas:  

Cancer

Asciminib (ABL001) hydrochloride is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM .
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-50868
CAS No.: 859212-16-1
Synonyms: INNO-406; NS-187
Target:  

Bcr-Abl Src Apoptosis

Research Areas:  

Cancer

Bafetinib is an orally active Lyn/Bcr-Abl tyrosine kinase inhibitor. Bafetinib enhances the activity of several pro-apoptotic Bcl-2 homology (BH) 3-pure proteins (Bim, Bad, Bmf, and Bik) through intrinsic apoptotic pathways regulated by the Bcl-2 family, and induces apoptosis of Ph + leukemia cells. Bafetinib has antitumor activity .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-13024
CAS No.: 1020172-07-9
Purity:  99.91%
Synonyms: DCC-2036
Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor, with IC50 values of 0.8 nM and 4 nM against Abl1 WT and Abl1 T315I, respectively. Rebastinib potently inhibits CYP2C8 (IC50 = 0.0533 μM) and CYP2C9 (IC50 = 2.54 μM). Rebastinib allosterically inhibits Tie2 with an IC50 of 0.63 nM. Rebastinib inhibits the transcriptional activity of FoxO1. Rebastinib inhibits SRC family kinases, KDR and FLT3 kinases. Rebastinib induces Apoptosis. Rebastinib exerts anti-tumor activity in breast cancer. Rebastinib exerts anti-angiogenic effects. Rebastinib increases myotube diameter and improves reduced contractility. Rebastinib can be used in research related to triple-negative breast cancer, luminal breast cancer, pancreatic neuroendocrine tumors, muscle atrophy, cancer cachexia, chronic myeloid leukemia, and B-lymphocytic leukemia .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-15666
CAS No.: 1257628-77-5
Purity:  99.65%
Synonyms: GZD824; HQP1351
Target:  

Bcr-Abl

Research Areas:  

Cancer

Olverembatinib (GZD824) is a potent and orally active pan-Bcr-Abl inhibitor. Olverembatinib potently inhibits a broad spectrum of Bcr-Abl mutants. Olverembatinib strongly inhibits native Bcr-Abl and Bcr-Abl T315I with IC50s of 0.34 nM and 0.68 nM, respectively. Olverembatinib has antitumor activity . Olverembatinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-15666A
CAS No.: 1421783-64-3
Purity:  99.81%
Synonyms: GZD824 dimesylate; HQP1351 dimesylate
Target:  

Bcr-Abl

Research Areas:  

Cancer

Olverembatinib (GZD824) dimesylate is a potent and orally active pan-Bcr-Abl inhibitor. Olverembatinib dimesylate potently inhibits a broad spectrum of Bcr-Abl mutants. Olverembatinib dimesylate strongly inhibits native Bcr-Abl and Bcr-Abl T315I with IC50s of 0.34 nM and 0.68 nM, respectively. Olverembatinib dimesylate has antitumor activity . Olverembatinib (dimesylate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-10253
CAS No.: 65678-07-1
Purity:  98.68%
Synonyms: Tyrphostin AG 1024
Research Areas:  

Endocrinology Cancer

AG1024 (Tyrphostin AG 1024) is a reversible, competitive and selective IGF-1R inhibitor with an IC50 of 7 μM. AG1024 inhibits phosphorylation of IR (IC50=57 μM). AG1024 induces apoptosis and has anti-cancer activity .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-15738
CAS No.: 778277-15-9
Purity:  99.95%
Target:  

Bcr-Abl

Research Areas:  

Cancer

GNF-5, the N-hydroxyethyl carboxamide analog of GNF-2, is an orally active Bcr-Abl inhibitor. GNF-5 has Bcr-Abl inhibition activity with an IC50 value of 0.22 µM. GNF-5 has good favorable pharmacokinetic properties. GNF-5 can be used for the research of kinds of cancer including chronic myelogenous leukemia (CML) and breast cancer .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-15749
CAS No.: 898280-07-4
Purity:  99.64%
Research Areas:  

Endocrinology Cancer

XL228 is a multi-targeted tyrosine kinase inhibitor with IC50s of 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src and Lyn, respectively.
loading...
    loading...